Theralase Technologies (TLT) Q3 2025 earnings summary

Executive summary

• Revenue for the nine months ended September 30, 2025, decreased 5% year-over-year to $590,573, with a net loss increasing 3% to $3,435,145.

• Gross margin remained stable at $290,830, representing 49% of revenue.

• Operational focus included advancing Study II, nearing full enrollment, and reporting promising interim clinical results.

Financial highlights

• Total revenue declined 5% to $590,573 from $622,984 year-over-year.

• Cost of sales decreased 10% to $299,743, improving as a percentage of revenue.

• Gross margin was $290,830 (49% of revenue), nearly unchanged from the prior year.

• Net loss increased 3% to $3,435,145, including $708,521 in non-cash charges.

• Research and development expenses rose 1% to $2,116,540, supporting Study II progress.

Outlook and guidance

• Study II enrollment expected to complete in 4Q2025, with data lock and regulatory submissions targeted for 1Q2027.

• Company continues to seek additional equity and non-dilutive funding to support clinical and commercial milestones.